Accepted for Publication: July 3, 2012.
Published Online: November 26, 2012. doi:10.1001/jamaneurol.2013.596
Author Contributions:Study concept and design: Haley, Wolfe, and Vernino. Acquisition of data: Haley, Charuvastra, Shell, Buhner, Marshall, Biggs, Hopkins, Wolfe, and Vernino. Analysis and interpretation of data: Haley, Shell, Biggs, Wolfe, and Vernino. Drafting of the manuscript: Haley, Shell, Hopkins, and Vernino. Critical revision of the manuscript for important intellectual content: Haley, Charuvastra, Shell, Buhner, Marshall, Biggs, Wolfe, and Vernino. Statistical analysis: Haley and Shell. Obtained funding: Haley. Administrative, technical, and material support: Haley, Charuvastra, Buhner, Marshall, Biggs, Hopkins, and Wolfe. Study supervision: Haley.
Conflict of Interest Disclosures: Dr Haley received an honorarium from Targeted Medical Pharma, Inc, for critical review of a Food and Drug Administration new drug application for a nonpharmaceutical medication to treat fatiguing illness of possible benefit to Gulf War veterans.
Funding/Support: This study was supported by Indefinite Delivery Indefinite Quantity contract VA549-P-0027, awarded and administered by the Department of Veterans Affairs Medical Center, Dallas, Texas; by grant DAMD17-01-1-0741 from the US Army Medical Research and Materiel Command; and by grant UL1RR024982-05, titled North and Central Texas Clinical and Translational Science Initiative, from the National Center for Research Resources, a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research.
Role of the Sponsor: The funding agencies had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Disclaimer: The content does not necessarily reflect the position or the policy of the federal government or the sponsoring agencies, and no official endorsement should be inferred.